Interaction of GHK Tripeptide with Receptors Targeted in Some Cancer Studies: A Theoretical Approach with Molecular Docking
Interaction of GHK Tripeptide with Receptors Targeted in Some Cancer Studies: A Theoretical Approach with Molecular Docking
Cancer, defined as the uncontrolled growth and proliferation of cells, is a serious disease seen in many people around the world. For this reason, a lot of work has been done and continues to be done by scientists for the diagnosis and treatment of cancer. It is known that various receptors are targeted in studies on cancers. In this study, ER, PR, EGFR and HER2 receptors, which are among the most frequently used target receptors, were selected. GHK is a tripeptide that has important benefits such as increasing cancer resistance and reversing cancer cells. In this study, the complex structures formed by the most commonly used target receptors (ER, PR, EGFR and HER2) and the GHK tripeptide were examined. These complex structures were obtained by molecular docking method that is a molecular modeling method used to predict how a receptor interacts with small molecules. As a result of the study, binding affinities, close interactions, and interaction types of GHK and receptors were determined, and interaction profiles with various drugs (such as tamoxifen, erlotinib and neratinib) in the literature were examined comparatively. In the light of the findings obtained in the studies, it was determined that the GHK tripeptide gave similar interaction profiles with the drugs used in cancer treatment.
___
- 1. D’arcy MS. Cell death: a review of the major forms of apoptosis,
necrosis and autophagy. Cell biology international. 2019;43(6):582-
92.
- 2. Acharya R, Chacko S, Bose P, Lapenna A, Pattanayak SP. Structure
based multitargeted molecular docking analysis of selected
furanocoumarins against breast cancer. Scientific reports.
2019;9(1):1-13.
- 3. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, et
al. Estrogen receptor alpha (ESR1) gene amplification is frequent in
breast cancer. Nature genetics. 2007;39(5):655-60.
- 4. Fowler AM, Alarid ET. Amping up estrogen receptors in breast
cancer. Breast Cancer Research. 2007;9:1-3.
- 5. Lange CA, Yee D. Progesterone and breast cancer. Women’s Health.
2008;4(2):151-62.
- 6. Swargiary G, Mani S. ER and PGR targeting ability of
phytocompounds derived from Centella asiatica and Andrographis
paniculata: an in-silico approach. Journal of Herbal Medicine.
2022;32:100541.
- 7. Dhiani BA, Nurulita NA, Fitriyani F. Protein-protein Docking
Studies of Estrogen Receptor Alpha and TRIM56 Interaction
for Breast Cancer Drug Screening. Indonesian Journal of Cancer
Chemoprevention. 2022;13(1):46-54.
- 8. Nilsson S, Gustafsson JÅ. Estrogen receptors: therapies targeted
to receptor subtypes. Clinical Pharmacology & Therapeutics.
2011;89(1):44-55.
- 9. Mani S, Swargiary G, Gulati S, Gupta S, Jindal D. Molecular
docking and ADMET studies to predict the anti-breast cancer effect
of aloin by targeting estrogen and progesterone receptors. Materials
Today: Proceedings. 2021.
- 10. Saghiri K, Daoud I, Melkemi N, Mesli F. QSAR study, molecular
docking/dynamics simulations and ADME prediction of 2-phenyl-
1H-indole derivatives as potential breast cancer inhibitors.
Biointerface Res Appl Chem. 2022;13(2):154.
- 11. Sing LC, Roy A, Hui LY, Mun CS, Rajak H, Karunakaran R, et al.
Multi-targeted molecular docking, drug-likeness and ADMET
studies of derivatives of few quinoline-and acridine-based
FDA-approved drugs for anti-breast cancer activity. Structural
Chemistry. 2022;33(3):649-69.
- 12. Prabhavathi H, Dasegowda K, Renukananda K, Karunakar P,
Lingaraju K, Raja Naika H. Molecular docking and dynamic
simulation to identify potential phytocompound inhibitors
for EGFR and HER2 as anti-breast cancer agents. Journal of
Biomolecular Structure and Dynamics. 2022;40(10):4713-24.
- 13. Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D,
Carneiro BA, et al. Targeting Epidermal Growth Factor Receptor in
triple negative breast cancer: New discoveries and practical insights
for drug development. Cancer treatment reviews. 2017;53:111-9.
- 14. Mueller KL, Yang Z-Q, Haddad R, Ethier SP, Boerner JL. EGFR/
Met association regulates EGFR TKI resistance in breast cancer.
Journal of molecular signaling. 2010;5(1):1-8.
- 15. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and
lung cancer. Annual Review of Pathology: Mechanisms of Disease.
2011;6:49-69.
- 16. de Castro-Carpeño J, Belda-Iniesta C, Sáenz EC, Agudo EH, Batlle
JF, Barón MG. EGFR and colon cancer: a clinical view. Clinical and
Translational Oncology. 2008;10:6-13.
- 17. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2
(HER2) in cancers: overexpression and therapeutic implications.
Molecular biology international. 2014;2014.
- 18. Tripathi S, Srivastava G, Sharma A. Computational Design of
Multi-Target Drugs Against Breast Cancer. Multi-Target Drug
Design Using Chem-Bioinformatic Approaches. 2019:443-58.
- 19. Landi L, Cappuzzo F. HER2 and lung cancer. Expert review of
anticancer therapy. 2013;13(10):1219-28.
- 20. Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment
of non-small cell lung cancer. Lung Cancer. 2015;87(3):220-5.
- 21. Budama-Kilinc Y, Kecel-Gunduz S, Cakir-Koc R, Aslan B, Bicak
B, Kokcu Y, et al. Structural characterization and drug delivery
system of natural growth-modulating peptide against glioblastoma
cancer. International Journal of Peptide Research and Therapeutics.
2021;27(3):2015-28.
- 22. Kokcu Y, Kecel-Gunduz S, Budama-Kilinc Y, Cakir-Koc R, Bicak
B, Zorlu T, et al. Structural analysis, molecular dynamics and
docking calculations of skin protective tripeptide and design,
characterization, cytotoxicity studies of its PLGA nanoparticles.
Journal of Molecular Structure. 2020;1200:127046.
- 23. Pickart L, Vasquez-Soltero JM, Pickart FD, Majnarich J. GHK, the
human skin remodeling peptide, induces anti-cancer expression
of numerous caspase, growth regulatory, and DNA repair genes.
Journal of Analytical Oncology. 2014;3(2):79-87.
- 24. Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A ‘metastasisprone’signature
for early-stage mismatch-repair proficient
sporadic colorectal cancer patients and its implications for possible
therapeutics. Clinical & experimental metastasis. 2010;27:83-90.
- 25. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al.
The Connectivity Map: using gene-expression signatures to connect
small molecules, genes, and disease. science. 2006;313(5795):1929-
35.
- 26. Pickart L, Margolina A. Modulation of Gene Expression in Human
Breast Cancer MCF7 and Prostate Cancer PC3 Cells by the Human
Copper-Binding Peptide GHK-Cu. OBM Genetics. 2021;5(2):1-18.
- 27. Matalka L, Ford A, Unlap M. The tripeptide, GHK, induces
programmed cell death in SH-SY5Y neuroblastoma cells. Journal
of Biotechnology & Biomaterials. 2012;2:1-4.
- 28. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA:
resetting the human genome to health. BioMed research
international. 2014;2014.
- 29. Bicak B, Gunduz SK. Computer-Aided Drug Design of Plant-
Based Compounds. Isolation, Characterization, and Therapeutic
Applications of Natural Bioactive Compounds: IGI Global; 2022. p.
320-45.
- 30. Gunduz SK, Bicak B, Ozel AE. Advancements in cancer
therapeutics: Computational drug design methods used in cancer
studies. Handbook of research on advancements in cancer
therapeutics: IGI Global; 2021. p. 89-115.
- 31. Tanenbaum DM, Wang Y, Williams SP, Sigler PB. Crystallographic
comparison of the estrogen and progesterone receptor’s ligand
binding domains. Proceedings of the National Academy of Sciences.
1998;95(11):5998-6003.
- 32. Madauss KP, Grygielko ET, Deng S-J, Sulpizio AC, Stanley
TB, Wu C, et al. A structural and in vitro characterization of
asoprisnil: a selective progesterone receptor modulator. Molecular
endocrinology. 2007;21(5):1066-81.
- 33. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal
growth factor receptor kinase domain alone and in complex with
a 4-anilinoquinazoline inhibitor. Journal of biological chemistry.
2002;277(48):46265-72.
- 34. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T,
et al. Design and synthesis of novel human epidermal growth factor
receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual
inhibitors bearing a pyrrolo [3, 2-d] pyrimidine scaffold. Journal of
medicinal chemistry. 2011;54(23):8030-50.
- 35. Trott O, Olson AJ. AutoDock Vina: improving the speed and
accuracy of docking with a new scoring function, efficient
optimization, and multithreading. Journal of computational
chemistry. 2010;31(2):455-61.
- 36. DeLano WL. Pymol: An open-source molecular graphics tool.
CCP4 Newsl Protein Crystallogr. 2002;40(1):82-92.
- 37. Biovia DS. Discovery studio modeling environment. Release; 2017.
- 38. Mustarichiei R, Levitas J, Arpina J. In silico study of curcumol,
curcumenol, isocurcumenol, and β-sitosterol as potential inhibitors
of estrogen receptor alpha of breast cancer. Medical Journal of
Indonesia. 2014;23(1):15-24.
- 39. Liu Y, Ma H, Yao J. ERα, a key target for cancer therapy: A review.
OncoTargets and therapy. 2020;13:2183.
- 40. Ariazi EA, Leitao A, Oprea TI, Chen B, Louis T, Bertucci AM, et al.
Exemestane's 17-hydroxylated metabolite exerts biological effects
as an androgen. Molecular cancer therapeutics. 2007;6(11):2817-27.
- 41. Li Z, Wei H, Li S, Wu P, Mao X. The role of progesterone receptors in
breast cancer. Drug Design, Development and Therapy. 2022:305-
14.
- 42. Pratama MRF, Poerwono H, Siswandono S. Design and molecular
docking of novel 5-O-Benzoylpinostrobin derivatives as anti-breast
cancer. Thai Journal of Pharmaceutical Sciences (TJPS). 2020;43(4).
- 43. Kesuma D, Siswandono S, Kirtishanti A. Molecular Docking And
Biological Activity Of N-(4-Methoxy)-Benzoyl-N’-Phenylthiourea
And N-(4-Trifluoro)-Benzoyl-N’-Phenylthiourea As Antibreast
Cancer Candidates. Rasayan Journal of Chemistry. 2022;15(2):1503-
8.
- 44. Garcia-Closas M, Brinton L, Lissowska J, Chatterjee N, Peplonska
B, Anderson W, et al. Established breast cancer risk factors by
clinically important tumour characteristics. British journal of
cancer. 2006;95(1):123-9.
- 45. Miše I, Vučić M, Maričević I, Šokčević M, Čurić-Jurić S. Histologic
subtypes of invasive lobular carcinoma in correlation with
tumor status and hormone receptors. Acta Clinica Croatica.
2010;49(3):275-81.
- 46. Özmen V. Türkiye'de Meme Kanseri: Klinik ve Histopatolojik
Özellikler (13.240 Olgunun Analizi). Meme Sagligi Dergisi/Journal
of Breast Health. 2014;10(2).